We’re reader-supported and may be paid when you visit links to partner sites. We don’t compare all products in the market, but we’re working on it!
Exopharm Limited is a biotechnology business based in Australia. Exopharm shares (EX1) are listed on the Australian Securities Exchange (ASX) and all prices are in Australian Dollars. Exopharm has a trailing 12-month revenue of around $4.2 million. If you're looking to buy shares, check out the steps below.
Our top pick for
US stocks
Our top pick for
ETF investing
Our top pick for
Overall broker
| 52-week range | $0.28 - $0.96 |
|---|---|
| 50-day moving average | $0.4891 |
| 200-day moving average | $0.628 |
| Target price | N/A |
| PE ratio | N/A |
| Dividend yield | N/A (0%) |
| Earnings per share (TTM) | $-0.065 |
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
Historical closes compared with the last close of A$0.49
| 1 week (2021-09-09) | -10.91% |
|---|---|
| 1 month (2021-08-16) | 3.16% |
| 3 months (2021-06-17) | -22.22% |
| 6 months (2021-03-17) | -36.36% |
| 1 year (2020-09-16) | 63.33% |
|---|---|
| 2 years (2019-09-16) | 18.07% |
| Revenue TTM | $4.2 million |
|---|---|
| Gross profit TTM | $61,104 |
| Return on assets TTM | -37.84% |
| Return on equity TTM | -70.91% |
| Profit margin | -202.02% |
| Book value | 0.12 |
| Market capitalisation | $84.9 million |
TTM: trailing 12 months
We're not expecting Exopharm to pay a dividend over the next 12 months.
Over the last 12 months, Exopharm 's shares have ranged in value from as little as $0.28 up to $0.96. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (AU average) beta is 1, while Exopharm 's is 0.9558. This would suggest that Exopharm 's shares are less volatile than average (for this exchange).
Exopharm Limited, a biopharmaceutical company, focuses on developing and commercializing human therapeutics using extracellular vesicles (EVs) as medicines in Australia. The company is developing Naïve EVs as regenerative medicines, including Plexaris for wound healing; and Cevaris used in inflammatory, immunomodulatory, and tissue remodeling activities. Its Engineered EVs products comprise Fortrexo CoV, an engineered EV product that reduce the duration and severity of SARS-CoV-2 infection in the early phase of a patient's exposure to COVID-19; and Plexodox, a platelet derived EV loaded with the approved anti-cancer drug doxorubicin as a novel and improved anticancer drug. The company was founded in 2013 and is headquartered in Melbourne, Australia.
Shares in the telecoms operator have jumped nearly 40% over the last 12 months.
This guide will show you step-by-step instructions on how to buy the IRON Titanium Token (TITAN) token as well as a list of exchanges you can trade it on.
This guide will show you step-by-step instructions on how to buy the Wabi (WABI) token as well as a list of exchanges you can trade it on.
This guide will show you step-by-step instructions on how to buy the Cindicator (CND) token as well as a list of exchanges you can trade it on.
This guide will show you step-by-step instructions on how to buy the MonaCoin (MONA) token as well as a list of exchanges you can trade it on.
This guide will show you step-by-step instructions on how to buy the Bluzelle (BLZ) token as well as a list of exchanges you can trade it on.
This guide will show you step-by-step instructions on how to buy the Whitecoin (XWC) token as well as a list of exchanges you can trade it on.
This guide will show you step-by-step instructions on how to buy the Storj (STORJ) token as well as a list of exchanges you can trade it on.
Despite the good news, Qantas shares closed flat following the announcement, but that could change in the coming weeks.
Shares in the lithium producer are up five-fold over the last 12 months.
